The G-BA took the opportunity to announce its work programme for 2023 at a press conference on 14 February 2023. The impartial G-BA Chair professor Josef Hecken highlighted in his introduction speech that the G-BA had made over 1,000 benefit assessment decisions since the introduction of AMNOG and the mandatory assessment of new medicines in Germany in 2011.
The G-BA expects 130 new AMNOG benefit assessment resolutions in 2023. To assess the evidence, the G-BA will commission either IQWiG or – in the case of new orphan drugs – the G-BA Office. So far, pharmaceutical companies have reserved 260 paid consultations with the G-BA in 2023 to get ready for the specific evidence requirements. Professor Hecken informed that all consultation appointments are, in fact, booked and the number of requests clearly surpasses the G-BA resources. According to him, the high demand shows “how well-established and exemplary across Europe AMNOG meanwhile is”.
Meriem Bouslouk-Marx in action. Photo by © Francisco Brasil